Ovarian cancer · 2 regimens
Cost vs Efficacy · 1 point
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Cisplatin and Cyclophosphamide Variant #01 | — | R 679 | 21d | — | — | — | — | — |
Melphalan monotherapy Variant #01 | — | R 71 | 42d | ~50.0 mo | ~22.2 mo | ~37 | ~R 2 636 PFS proxy · indirect | 7 |
2 of 2 regimens shown